ANP to participate in PPMD development of new Community-Led Duchenne Guidance for FDA•
ANP to serve as a member of the Pharmaceutical Advisory Board for the DMD Guidance documentAntisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], (the Company) is pleased to advise that the Company’s US-based Medical Director, Gil Price, MD, will serve as a member of the Pharmaceutical Advisory Board (PAB) for the development of the New Duchenne Guidance by Parent Project Muscular Dystrophy (PPMD) for the US FDA.
Working closely with the Steering Committee and Working Group Chairs, comprised of individuals representing the patient advocate, caregiver, clinician, researcher, academic, and pharmaceutical industry, the PAB will focus on ensuring perspectives from companies with an interest Duchenne community are represented throughout the guidance.
PPMD successfully developed the first-ever patient group initiated draft guidance for comp
ANP to participate in PPMD development of new Community-Led...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |